Abstract library

153 results for "SDH mutation".
#2920 Mutation Spectrums Analysis of Colorectal Adenocarcinoma and Neuroendocrine Neoplasm Based on Same Genetic Background to Reveal Tumorigenesis
Introduction: The tumorigenesis of neuroendocrine neoplasm (NEN) are still ambiguous. The therapies of NENs in colon or rectum refer to adenocarcinomas (AC) when tumor metastasis, but the response was unsatisfactory which inspired us to explore the mutation difference.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Wen Cai
Authors: Cai W, Ge W, Wu D, Mao J, ...
#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MSc Andreas Venizelos
#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia
Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Nicole Unger
Authors: Unger N, Theurer S, Herold T, Weber F, ...
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...
#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs Kris Samsom
#2972 Characteristics and Management of Paragangliomas, 10 Years Experience
Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Emilia Sardo
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande
#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Authors: Kong G, Callahan J, Prall O, Michael M, ...
#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics
Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Caterina Vicentini